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2806Drug-eluting stents (DES) using
a cobalt chromium (CoCr) alloy
have improved clinical outcomes
compared with ﬁrst-generation
DES and have raised the bar
for clinical performance (1–5).
The CoCr alloy has made it
possible to maintain the radio-
opacity of coronary stents while
reducing the stent strut thick-
ness compared with stainless steel
(6,7). The newest addition to
the newer-generation CoCr-DES
lineup has been the CoCr-based
zotarolimus-eluting stent (ZES)
(Resolute, Medtronic, Minneap-
olis, Minnesota), which showed
equivalent outcomes compared
with the CoCr-based everolimus-
eluting stent (EES) in the
RESOLUTE All-Comers ran-
domized trial (8,9). However,
there still exist unmet needs,
such as improved radial strength
and visibility, which have driventhe development of a novel platinum chromium (PtCr) alloy.
PtCr-based stents were shown to have higher radio-opacity,
more resistant radial strength, and enhanced conformability
(10,11). A recent trial proved the noninferiority of the PtCr-
EES (Promus Element, Boston Scientiﬁc, Natick, Massa-
chusetts) compared with CoCr-EES in terms of clinical
outcomes (12). However, this stent has not been tested in a
broader population and compared with the CoCr-ZES.
Data suggesting similar safety of PtCr-EES and CoCr-
ZES in recent meta-analyses have been from only indirect
comparisons (13,14) without evidence from direct, large-
scale, head-to-head prospective trials. Further, the issue of
longitudinal stent deformation (LSD) has been raised
regarding thin-strut stents (15–18), with the PtCr-EES
platform implicated as a potential risk factor (19,20).
This randomized trial was performed to test whether
the newly developed PtCr-EES is noninferior to the
CoCr-ZES in all-comers receiving percutaneous coronaryHospital, Seoul, Republic of Korea; yDankook
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zzDaegu Catholic University Medical Center,
Fatima Hospital, Daegu, Republic of Korea;intervention (PCI) with regard to target lesion failure
(TLF). Moreover, procedural angiograms of all possible
patients were reviewed by a core laboratory to address the
issue of LSD.Methods
Study design. The HOST–ASSURE (Harmonizing Opti-
mal Strategy for Treatment of coronary artery stenosis–
sAfety & effectiveneSS of drug-elUting stents & anti-platelet
REgimen) was a prospective, randomized, single-blind,
blinded endpoint evaluation, multicenter trial conducted
at 40 sites in South Korea. The study design has been
previously published (21). Brieﬂy, the study had a 2  2
factorial design, in which randomization was performed for
the type of DES and the type of 1-month intensiﬁed an-
tiplatelet therapy followed by conventional dual antiplatelet
therapy. Participating patients were randomized 2:1 to
either PtCr-EES or CoCr-ZES and 1:1 to either triple
antiplatelet therapy or double-dose dual antiplatelet ther-
apy. The trial was coordinated by the investigators at the
Cardiovascular Clinical Research Center at Seoul National
University Hospital. The data were independently man-
aged by a contract research organization, Dream CIS, Inc.
(Seoul, Korea) The primary data analysis was performed by
the investigators, with cooperation from Dream CIS, Inc.
The executive committee, with assistance from the steering
committee, was responsible for the study design, conduct,
and management; manuscript preparation; and the decision
to submit the paper for publication. An independent data
safety monitoring board reviewed the unblinded data. The
study was approved by all local ethics committees at the
participating centers and was performed in accordance with
the Declaration of Helsinki; written informed consent was
obtained from all participants.
Patients. Trial participants were 18 years of age or older
and had at least 1 clinically signiﬁcant stenotic lesion
amenable to PCI in the coronary artery, venous, or arterial
bypass grafts. The trial entry criteria were broad with no
exclusion criteria for lesion type, the number of stents used,
the number of lesions treated, or the diagnosis at presenta-
tion. Major exclusion criteria were severe left ventricular
systolic dysfunction (ejection fraction <25%), cardiogenickkkGyeongsang National University Hospital, Jinju, Republic of Korea; and the
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3,755 Patients
Enrolled and Randomized
2,503 Allocated to PtCr-EES
• 2,450 received at least 1 allocated stent
- 2,411 received allocated stents only
- 39 received both allocated and not-allocated stents
• 39 received not-allocated stents
• 14 received no stents (balloon angioplasty only)
1,252 Allocated to CoCr-ZES
• 1,186 received at least 1 allocated stent
-1,179 received allocated stents only
- 7 received both allocated and not-allocated stents
• 61 received not-allocated stents
• 5 received no stents (balloon angioplasty only)
2,470 (98.7%) Completed 1-Year Clinical Follow-Up 1,236 (98.7%) Completed 1-Year Clinical Follow-Up
9 withdrew
7 voluntarily
2 by physician’s decision
7 were lost to follow up
17 withdrew
14 voluntarily
3 by physician’s decision
16 were lost to follow up
2,503 Analyzed According to Intention to Treat 1,252 Analyzed According to Intention to Treat
17,283 Patients
Assessed for Eligibility
Figure 1 Trial Proﬁle
A total of 3,755 patients were randomized 2:1 to platinum chromium (PtCr)-based everolimus-eluting stent (EES) or cobalt chromium (CoCr)-based zotarolimus-eluting stent
(ZES). Clinical outcomes were analyzed according to the intention-to-treat basis.
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2807shock, an increased risk of bleeding as evidenced by a history
of bleeding diathesis, known coagulopathy, gastrointestinal
or genitourinary bleeding within the prior 3 months, or
major surgery within 2 months. Details of the eligibility
criteria are described in the Online Appendix (Online
Table 1).
Study procedures and endpoints. Patients were randomly
assigned to either PtCr-EES or CoCr-ZES via a web-based
online randomization system after diagnostic angiography
and before PCI. The PCI was performed according to the
standard techniques. The primary endpoint was TLF at 12
months, deﬁned as a composite of cardiac death, target
vessel–related myocardial infarction (TV-MI), and target
lesion revascularization (TLR). Secondary endpoints
included all of the individual components of the primary
outcome along with stent thrombosis, patient-oriented
clinical outcome, and all components of patient-oriented
clinical outcome (all-cause death, all-cause myocardial
infarction, and any repeat revascularization). Clinical events
were deﬁned on the basis of the recommendations of the
Academic Research Consortium (ARC) (22). All deaths
were considered cardiac unless a deﬁnite noncardiac cause
could be established. Myocardial infarction was deﬁned as
the presence of clinical signs of myocardial infarction com-
bined with a creatine kinase MB fraction or troponin-T or -I
increase higher than the upper normal limit (23). Cardiacenzyme measurements were not routinely followed serially
after PCI for all patients, but were allowed when clinically
indicated. Stent thrombosis was deﬁned as deﬁnite or
probable stent thrombosis according to the ARC classiﬁca-
tion (22). The independent clinical event adjudication
committee, whose members were unaware of the study
group assignments, assessed all of the clinical endpoints.
The primary analysis was on an intention-to-treat basis.
Angiographic analysis. Detailed methods of angiographic
analysis are described in the Online Appendix. In brief, a
qualitative analysis was performed to assess the presence
of LSD, which was deﬁned as any inconsistency in the
radiodensity pattern along the length of the stent, or other
gross irregularities or deformities. For quantitative assess-
ment for the possibility of systemic longitudinal shortening
of the stent, we measured the nominal stent length ratio
(NSR), deﬁned as the ratio of the ﬁnal stent length after
completion of the entire procedure to the nominal stent
length.
Statistical analysis. We estimated that 3,750 patients
would be required (using a sampling ratio of PtCr-EES to
CoCr-ZES at 2:1) in the study to have >80% power with a
1-sided a of 2.5% to show noninferiority of the PtCr-EES
compared with CoCr-ZES at hazard ratio (HR) 1.5, with
the assumption of a 5% attrition rate and an assumed TLF
rate of 6.5% at 12 months for CoCr-ZES. The primary
Table 1 Baseline Patient Characteristics
PtCr-EES
(n ¼ 2,503)
CoCr-ZES
(n ¼ 1,252)
Age, yrs 63.1  10.8 63.5  10.7
Male 1,746 (69.8) 820 (65.6)
Body mass index, kg/m2 24.6  3.2 24.7  3.2
Hypertension 1,706 (68.2) 852 (68.1)
Diabetes 795 (31.8) 401 (32.0)
Dyslipidemia 1,601 (64.0) 822 (65.7)
Current smoker 823 (32.9) 369 (29.5)
Chronic renal failure 59 (2.4) 36 (2.9)
Peripheral artery disease 41 (1.6) 27 (2.2)
Cerebrovascular disease 172 (6.9) 79 (6.3)
Previous PCI 247 (9.9) 120 (9.6)
Previous bypass surgery 16 (0.6) 10 (0.8)
Previous myocardial infarction 116 (4.6) 49 (3.9)
Congestive heart failure 41 (1.6) 13 (1.0)
Clinical diagnosis
Silent ischemia 119 (4.8) 63 (5.0)
Stable angina 746 (29.8) 367 (29.3)
Unstable angina 903 (36.1) 476 (38.0)
NSTEMI 452 (18.1) 209 (16.7)
STEMI 283 (11.3) 137 (10.9)
Baseline laboratory ﬁndings
Left ventricular ejection fraction, % 59.9  10.4 60.4  10.2
Hemoglobin, g/dl 13.7  1.7 13.7  1.7
Platelet count  103/mm 227  61 227  64
Serum creatinine, mg/dl 1.00  0.73 1.00  0.87
Total cholesterol, mg/dl 177  43 178  45
Triglyceride, mg/dl 138  87 144  107
HDL cholesterol, mg/dl 44  12 44  11
LDL cholesterol, mg/dl 110  41 109  38
Procedural data
Angiographic disease extent
1-vessel disease 1,150 (45.9) 580 (46.3)
2-vessel disease 807 (32.2) 400 (31.9)
3-vessel disease 546 (21.8) 272 (21.7)
Target lesions to be treated
1 1,766 (70.6) 909 (72.6)
2 570 (22.8) 286 (22.8)
3 or more 167 (6.7) 57 (4.6)
Use of IVUS or OCT 1,037 (41.4) 494 (39.5)
Use of glycoprotein IIb/IIIa
inhibitors
55 (2.2) 37 (3.0)
Lesion data (n ¼ 3,426) (n ¼ 1,661)
Target vessel location
Left main artery 74 (2.2) 37 (2.2)
Left anterior descending artery 1,623 (47.4) 852 (51.3)
Left circumﬂex artery 751 (21.9) 324 (19.5)
Right coronary artery 978 (28.5) 448 (27.0)
ACC/AHA classiﬁcation B2/C type 1,662 (49.7) 842 (51.7)
Total occlusion 422 (12.3) 193 (11.6)
Thrombus-containing 45 (1.3) 25 (1.5)
Bifurcation 874 (25.6) 420 (25.3)
Continued in the next column
Table 1 Continued
PtCr-EES
(n ¼ 2,503)
CoCr-ZES
(n ¼ 1,252)
Medications at discharge
Aspirin 2,485 (99.3) 1,247 (99.6)
Clopidogrel 2,483 (99.2) 1,246 (99.5)
b-blocker 1,710 (68.3) 845 (67.5)
Calcium-channel blocker 526 (21.0) 236 (18.8)
ACE inhibitor or ARB 1,636 (65.4) 829 (66.2)
Statin 2,122 (84.8) 1,076 (85.9)
Values are mean  SD or n (%).
ACC/AHA ¼ American College of Cardiology/American Heart Association; ACE ¼ angiotensin-
converting enzyme; ARB ¼ angiotensin receptor blocker; CoCr-ZES ¼ cobalt chromium
zotarolimus-eluting stent; HDL ¼ high-density lipoprotein; IVUS ¼ intravascular ultrasound; LDL ¼
low-density lipoprotein; NSTEMI ¼ non–ST-segment elevation myocardial infarction; OCT ¼ optical
coherence tomography; PCI ¼ percutaneous coronary intervention; PtCr-EES ¼ platinum chromium
everolimus-eluting stent; STEMI ¼ ST-segment elevation myocardial infarction.
Park et al. JACC Vol. 63, No. 25, 2014
The HOST-ASSURE Trial July 1, 2014:2805–16
2808analysis was performed on an intention-to-treat basis.
Detailed methods of statistical analysis are described in the
Online Appendix.Results
Baseline characteristics and procedural results. From
June 2010 to November 2011, a total of 3,755 patients were
enrolled at 40 centers in South Korea. These patients were
randomly allocated to PtCr-EES (n ¼ 2,503 patients, 3,426
lesions) or CoCr-ZES (n ¼ 1,252 patients, 1,661 lesions).
Figure 1 shows the trial proﬁle and the study ﬂow of the
patients. The baseline patient characteristics are shown in
Table 1 and the baseline lesion and procedural characteris-
tics in Table 2. The baseline characteristics were mostly well
balanced and comparable between the 2 groups except for
male sex and smoking, which were slightly more frequent in
the PtCr-EES group.
Table 3 compares the use of antiplatelet agents in each
group during the follow-up duration. There were no signif-
icant differences at any follow-up period in terms of the use of
aspirin, clopidogrel, or cilostazol. Overall compliance to dual
antiplatelet therapy was 91.6% at 1-year follow-up and did
not differ signiﬁcantly at any time between the stent groups.
Clinical outcomes up to 1 year. At 12 months post-PCI,
the primary endpoint of TLF (the composite of cardiac
death, TV-MI, and TLR) occurred in 72 patients (2.9%) in
the PtCr-EES group and 36 patients (2.9%) in the CoCr-
ZES group (Table 4, Fig. 2A). We conﬁrmed the non-
inferiority of PtCr-EES with an absolute risk difference of
0% and an upper limit of the 1-sided 97.5% HR of 1.499
(p ¼ 0.0247 for noninferiority; pre-speciﬁed noninferiority
HR margin: 1.5) (Fig. 2B). Regarding superiority, there was
no signiﬁcant difference between the 2 treatment groups
(HR: 1.00; 95% conﬁdence interval [CI]: 0.67 to 1.50;
p ¼ 0.983 for superiority). The results of the per-protocol
analysis were similar to the intention-to-treat analysis
(TLF rates: 2.8% vs. 2.8%) with 97.5% upper CI marginally
exceeding the pre-speciﬁed margin (HR: 1.00; 95% CI: 0.66
to 1.52; p ¼ 0.028 for noninferiority; p ¼ 0.999 for superi-
ority) (Fig. 2C, Online Table 2). The individual rates of
cardiac death, TV-MI, and TLR were not signiﬁcantly
different between the 2 groups (Table 4, Figs. 2D to 2F).
Patient-oriented outcomes were also similar, and occurred
Table 2 Characteristics of Revascularization Procedures
Variable
PtCr-EES
(n ¼ 3,426)
CoCr-ZES
(n ¼ 1,661) p Value
Before index procedure
Lesion length, mm 19.3  11.8 19.8  12.4 0.229
Reference vessel diameter, mm 3.00  0.50 3.00  0.50 0.457
Minimum lumen diameter, mm 0.81  0.50 0.81  0.50 0.657
Percent stenosis, % 73.1  15.4 72.8  15.5 0.470
SYNTAX score 12.1  8.0 12.4  8.1 0.299
After index procedure
SYNTAX score 4.0  5.4 4.0  5.4 0.852*
Number of stents
Per lesion 1.19  0.45 1.17  0.43 0.301
Per patient 1.62  0.92 1.56  0.85 0.061
Maximal stent diameter, mm
Per lesion 3.15  0.46 3.16  0.44 0.797
Per patient 3.26  0.45 3.24  0.44 0.281
Total stent length, mm
Per lesion 27.7  13.3 28.7  14.6 0.022
Per patient 37.6  24.2 37.9  25.0 0.764
Adjunctive ballooning 2,369 (69.1) 1,140 (68.6) 0.710
Balloon diameter, mm 3.04  0.56 3.03  0.55 0.532
Maximal Inﬂation diameter, mm 3.22  0.62 3.20  0.57 0.387
Minimum lumen diameter, mm
In-stent 2.61  0.43 2.62  0.45 0.465
In-segment 2.23  0.53 2.21  0.52 0.397
Diameter stenosis, %
In-stent 11.0  7.4 11.2  8.1 0.538
In-segment 21.5  11.2 22.2  11.4 0.051
Acute gain, mm
In-stent 1.80  0.53 1.81  0.55 0.798
In-segment 1.42  0.58 1.40  0.59 0.275
Successful outcome
Lesion 3,388 (99.5) 1,643 (99.5) 0.947
Device 3,387 (99.4) 1,649 (99.8) 0.054
Procedure 3,390 (99.5) 1,644 (99.5) 0.875
Values are mean  SD or n (%). *Comparison was performed with the Wilcoxon rank sum test.
SYNTAX ¼ SYNergy between PCI with TAXUS and Cardiac Surgery; other abbreviations as in Table 1.
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2809in 5.2% and 4.5% of the PtCr-EES and CoCr-ZES groups,
respectively (HR: 1.20; 95% CI: 0.88 to 1.64; p ¼ 0.187).
Subgroup analyses of the primary outcome showed consistent
ﬁndings and no signiﬁcant interaction between different
subgroups and the allocated stent except for reference vessel
diameter (Fig. 3). There were no signiﬁcant interactions be-
tween the allocated stent and the allocated antiplatelet therapy
regimen with regard to any clinical endpoint including TLF.
At 12 months, ARC-deﬁned deﬁnite and probable stent
thrombosis occurred in 0.4% and 0.7%, respectively, in the
2 groups (p ¼ 0.229). There were no signiﬁcant differences
between the 2 stents regarding deﬁnite, probable, and possible
stent thrombosis as well as acute, subacute, or late stent
thrombosis (Table 5, Online Fig. 1). Details of individual
cases of the stent thrombosis are described in Online Table 3.
Angiographic analysis: longitudinal stent deformation.
Of 3,755 patients (5,087 lesions) enrolled in the study, the
baseline procedural angiograms were available and readable
in 3,711 patients (5,010 lesions). The occurrence of LSDwas analyzed using the baseline procedural angiograms in
these patients: 2,471 patients (3,367 lesions) in the PtCr-
EES group and 1,240 patients (1,643 lesions) in the
CoCr-ZES group. LSD was observed in 7 patients in
the PtCr-EES group (7 stents, incidence rate: 0.21%) and in
no patients in the CoCr-ZES group (p ¼ 0.104). The mean
NSR was lower in the PtCr-EES group compared with the
CoCr-ZES group (mean NSR 0.92  0.07 vs. 0.93  0.07;
p < 0.001) (Fig. 4). The speciﬁc details of the 7 LSD cases
are summarized in Table 6. Of these cases, none were asso-
ciated with future adverse clinical events up to 1 year. Only 1
case required an additional stent implantation during the
baseline procedure (Fig. 5). LSD occurred during stent im-
plantation while advancing adjunctive balloon catheter or
while withdrawing the trapped intravascular ultrasound
catheter, guidewire, or stent leading to deep engagement of
the guiding catheter. In all cases, the proximal part of the
stent was the site of deformation and resulted in signiﬁcant
shortening of the stent.
Table 3 Use of Antiplatelet Agents During Follow-Up
PtCr-EES
(n ¼ 2,503)
CoCr-ZES
(n ¼ 1,252) p Value
Aspirin
At 1 month 2,476/2,490 (99.4) 1,244/1,248 (99.7) 0.314
At 3 months 2,431/2,466 (98.6) 1,218/1,227 (99.3) 0.070
At 9 months 2,351/2,416 (97.3) 1,186/1,213 (97.8) 0.401
At 12 months 2,277/2,373 (96.0) 1,165/1,204 (96.8) 0.232
Clopidogrel
At 1 month 2,476/2,490 (99.4) 1,242/1,249 (99.4) 0.995
At 3 months 2,426/2,469 (98.3) 1,214/1,228 (98.9) 0.162
At 9 months 2,347/2,412 (97.3) 1,188/1,215 (97.8) 0.393
At 12 months 2,218/2,373 (93.5) 1,140/1,205 (94.6) 0.181
Cilostazol
At 1 month 1,168/2,490 (46.9) 587/1,248 (47.0) 0.941
At 3 months 172/2,463 (7.0) 95/1,227 (7.7) 0.402
At 9 months 103/2,409 (4.3) 45/1,211 (3.7) 0.422
At 12 months 97/2,364 (4.1) 53/1,201 (4.4) 0.663
Dual antiplatelet therapy
At 1 month 2,469/2,490 (99.2) 1,242/1,249 (99.4) 0.344
At 3 months 2,415/2,470 (97.8) 1,212/1,228 (98.7) 0.054
At 9 months 2,317/2,416 (95.9) 1,176/1,215 (96.8) 0.187
At 12 months 2,163/2,374 (91.1) 1,116/1,205 (92.6) 0.125
Values are n/N (%).
Abbreviations as in Table 1.
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2810Discussion
This was 1 of the largest direct stent comparison studies ever
performed to test the noninferiority of PtCr-EES against
the CoCr-ZES, the 2 most recently introduced and now
most commonly used DES. Furthermore, we systemicallyTable 4 Cumulative Incidence of Clinical Events
PtCr-EES
(n ¼ 2,503)
Target lesion failure 72 (2.88)
All-cause death 56 (2.24)
Cardiac death 34 (1.36)
All-cause MI 28 (1.12)
Target vessel-related MI 24 (0.96)
Repeat revascularization 74 (2.96)
Target lesion revascularization 31 (1.24)
Target vessel revascularization 42 (1.68)
Cerebrovascular accident 17 (0.68)
Ischemic 15 (0.60)
Hemorrhagic 2 (0.08)
All PLATO bleeding 45 (1.80)
Major bleeding 27 (1.08)
Major, life-threatening 4 (0.16)
Major, other 23 (0.92)
Minor bleeding 18 (0.72)
Target vessel failure 82 (3.28)
Patient-oriented clinical outcome 135 (5.39)
Values are n (%). Target vessel failure was a composite of cardiac death
revascularization; patient-oriented clinical outcome was a composite of all-c
PLATO ¼ PLATelet inhibition and patient Outcomes; other abbreviations aaddressed the issue of LSD in over 5,000 lesions. The major
ﬁndings of this study are as follows:
1. PtCr-EES was noninferior to CoCr-ZES at 1 year
regarding TLF, the composite of cardiac death,
nonfatal TV-MI, and ischemia-driven TLR. Also, theUp to 1 Year
CoCr-ZES
(n ¼ 1,252) HR (95% CI) p Value
36 (2.88) 1.00 (0.67–1.50) 0.983
20 (1.60) 1.40 (0.84–2.34) 0.194
17 (1.36) 1.00 (0.56–1.79) 0.997
17 (1.36) 0.83 (0.45–1.51) 0.533
13 (1.04) 0.93 (0.47–1.82) 0.822
33 (2.64) 1.13 (0.75–1.70) 0.557
15 (1.20) 1.04 (0.56–1.93) 0.900
23 (1.84) 0.92 (0.55–1.53) 0.746
8 (0.64) 1.07 (0.46–2.47) 0.879
6 (0.48) 1.26 (0.49–3.24) 0.636
2 (0.16) 0.50 (0.07–3.55) 0.489
25 (2.00) 0.90 (0.55–1.47) 0.674
16 (1.28) 0.84 (0.45–1.57) 0.591
4 (0.32) 0.50 (0.13–2.00) 0.327
13 (1.04) 0.89 (0.45–1.75) 0.725
9 (0.72) 1.00 (0.45–2.23) 0.996
42 (3.35) 0.98 (0.68–1.42) 0.919
55 (4.39) 1.24 (0.90–1.69) 0.187
, target vessel–related myocardial infarction (MI), and target vessel
ause death, all-cause MI, and repeat revascularization.
s in Table 1.
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Figure 2 Clinical Outcomes
(A) Kaplan-Meier cumulative event curves up to 12 months are shown for target lesion failure. (B) A noninferiority margin was pre-deﬁned as hazard ratio (HR) of 1.5 and a
p value function curve for hypothesis testing. (C) Target lesion failure by per-protocol analysis. (D to F) Event curves for cardiac death (D), nonfatal target vessel–related
myocardial infarction (E), and ischemia-driven target lesion revascularization (F). CI ¼ conﬁdence interval; other abbreviations as in Figure 1.
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Subgroup
Target Lesion Failure
– event/total (%) Hazard Ratio (95% Confidence Interval) P Value forInteraction
PtCr-EES CoCr-ZES
Age 0.395 
)4.4(716/72)0.4(2811/74sraey56≥ 0.91 (0.57 -1.46)
)4.1(536/9)9.1(1231/52sraey56< 1.35 (0.63 -2.90)
Sex 0.371 
)8.2(028/32)5.2(6471/34neM 0.88 (0.53 -1.46)
)0.3(234/31)8.3(757/92nemoW 1.29 (0.67 -2.48)
Acute Coronary Syndrome 0.779 
)2.3(228/62)1.3(8361/05seY 0.97 (0.60 -1.56)
)3.2(034/01)5.2(568/22oN 1.09 (0.52 -2.31)
Diabetes Mellitus 0.912 
)7.3(104/51)6.3(597/92seY 0.97 (0.52 -1.81)
)5.2(158/12)5.2(8071/34oN 1.03 (0.61 -1.74)
Renal Dysfunction 0.554
)5.6(26/4)9.8(321/11seY 1.39 (0.44 -4.47)
)7.2(0911/23)6.2(0832/16oN 0.96 (0.62 -1.47)
Number of Lesions to be Treated 0.114 
)4.2(909/22)0.3(6671/35enO 1.25 (0.76 -2.06)
More than two 19/737 (2.6) 14/343 (4.1) 0.63 (0.32 -1.25)
Lesion Length 0.346
)7.1(836/11)1.2(7621/72mm02≤ 1.24 (0.61 -2.50)
)5.4(764/12)7.3(139/43mm02> 0.82 (0.47 -1.41)
Reference Vessel Diameter 0.030 
)0.5(464/32)2.3(389/13mm57.2≤ 0.63 (0.37 -1.08)
)7.1(777/31)6.2(6841/93mm57.2> 1.58 (0.85 -2.97)
Multivessel Stenting 0.471 
)0.4(523/31)3.3(546/12seY 0.82 (0.41 -1.63)
)5.2(729/32)7.2(8581/15oN 1.11 (0.68 -1.82)
Allocated Antiplatelet Arm 0.885 
Triple Antiplatelet 37/1253 (3.0) 19/626 (3.0) 0.97 (0.56 -1.69)
Double Dose Dual Antiplatelet 35/1250 (2.8) 17/626 (2.7) 1.04 (0.58 -1.85)
)9.2(2521/63)9.2(3052/27llarevO 1.00 (0.67 -1.50)
0.25 0.5 1 2 4
Favors PtCr-EES Favors CoCr-ZES
Figure 3 Subgroup Analysis
Target lesion failure according to various subgroups. The squares indicate the odds ratios and the horizontal lines indicate 95% conﬁdence intervals.
Abbreviations as in Figure 1.
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2812individual outcomes were very similar between the 2
stents.
2. Both stents demonstrated outstanding safety as well as
efﬁcacy, with stent thrombosis rates below 1% and
TLF rates below 3% in an enriched PCI population of
all-comers.
3. LSD was observed only in PtCr-EES, but its inci-
dence was very rare and it was not associated with
future adverse clinical events.
Newer-generation DES have signiﬁcantly improved clinical
outcomes compared with ﬁrst-generation DES. In partic-
ular, CoCr-based EES, the oldest of the newer-generation
DES, have shown improved clinical results in various
trials and meta-analyses (1–5). The newest addition to the
CoCr alloy-based DES line-up has been the CoCr-ZES. In
the RESOLUTE All-Comers trial, CoCr-ZES was shown
to be noninferior to CoCr-EES regarding stent- and
patient-speciﬁc clinical outcomes (8,9). We also reported
similar clinical performance of the 2 stents from an all-comer
registry (24).Compared with the earlier-generation DES, 1 of the
major advantages of the CoCr stent platform was the
reduction in stent strut thickness. In previous stainless steel
stent platforms, the visibility of the stent decreases signiﬁ-
cantly as the stent strut thickness is reduced, as was evi-
denced in the stainless steel-based paclitaxel-eluting stent
(Taxus Liberte, Boston Scientiﬁc). Thus, the CoCr-based
stents have supplanted stainless steel stents as the most
commonly used coronary stents in the world. However,
CoCr stents have several important limitations. Radial
strength and recoil are inferior to stainless steel stents and
radio-opacity, although better than with stainless steel
stents, is still suboptimal, particularly with the newest thin-
strut CoCr stents. The PtCr alloy was developed to address
these limitations and was shown to have greater radial
strength, less recoil, and greater radio-opacity than its CoCr
counterparts (10,11). From bench data, the PtCr alloy
showed low thrombogenicity and a high degree of endo-
thelial surface coverage (25). Clinically, PtCr-EES was pre-
viously shown to be noninferior to CoCr-EES regarding
TLF at 1 and 2 years in the PLATINUM (A Prospective,
Table 5 Cumulative Incidence of Stent Thrombosis Up to 1 Year
PtCr-EES
(n ¼ 2,503)
CoCr-ZES
(n ¼ 1,252) p Value
Deﬁnite or probable ST 9 (0.36) 8 (0.67) 0.229
Acute deﬁnite or probable ST 1 (0.04) 1 (0.08) 1.000
Subacute deﬁnite or probable ST 7 (0.28) 6 (0.50) 0.379
Early deﬁnite or probable ST 8 (0.32) 7 (0.58) 0.273
Late deﬁnite or probable ST 1 (0.04) 1 (0.08) 1.000
Deﬁnite ST 5 (0.20) 3 (0.25) 1.000
Acute deﬁnite ST 0 (0.00) 1 (0.08) 0.333
Subacute deﬁnite ST 5 (0.20) 1 (0.08) 0.671
Early deﬁnite ST 5 (0.20) 2 (0.17) 1.000
Late deﬁnite ST 0 (0.00) 1 (0.08) 0.333
Probable ST 4 (0.16) 5 (0.42) 0.171
Acute probable ST 1 (0.04) 0 (0.00) 1.000
Subacute probable ST 2 (0.08) 5 (0.42) 0.045
Early probable ST 3 (0.12) 5 (0.42) 0.127
Late probable ST 1 (0.04) 0 (0.00) 1.000
Possible ST 15 (0.60) 6 (0.50) 0.642
Acute possible ST 0 (0.00) 0 (0.00) NA
Subacute possible ST 0 (0.00) 0 (0.00) NA
Early possible ST 0 (0.00) 0 (0.00) NA
Late possible ST 15 (0.60) 6 (0.50) 0.642
Values are n (%). Stent thrombosis (ST) was deﬁned according to the deﬁnition of the Academic Research Consortium consensus.
NA ¼ not available; other abbreviations as in Table 1.
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2813Randomized, Multicenter Trial to Assess an Everolimus-
Eluting Coronary Stent System [PROMUS Element] for
the Treatment of Up to Two de Novo Coronary Artery
Lesions) trial (12). We hypothesized that these potentialA Nominal Stent Length Ratio
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2814inadvertent LSD (15–18). LSD raised concerns about
possible adverse events or ST. Most reports were anecdotal
case reports with no data from comprehensively performed
prospective trials. In a study of pooled angiographic evaluation
of the PERSEUS (Prospective Evaluation in a Randomized
Trial of the Safety and Efﬁcacy of the Use of the TAXUS
Element Paclitaxel-Eluting Coronary Stent System for the
Treatment of De Novo Coronary Artery Lesions) and
PLATINUM trials, PtCr-EES did not differ from stainless
steel–based or CoCr-based stents in terms of the nominal
stent length ratio, and there were no cases of LSD (16).
However, bench testing showed that PtCr-EES had signiﬁ-
cantly weaker resistance against longitudinal compressive
forces compared with other stent platforms, which may be due
to its offset peak-to-peak design (15–19,26). In the present
study, after meticulous review of over 5,000 stents by an
angiographic core laboratory, LSD was observed only in the
PtCr-EES group and not in the CoCr-ZES group. However,
the events were so rare (0.2% in the PtCr-EES group) that this
difference was not statistically signiﬁcant. The problem
observed in this study with the proximal portion of the stent
being vulnerable to LSD has recently been addressed by the
manufacturer through the addition of connectors to the
proximal stent struts in the design of the new version of the
PtCr-EES, the PromusPremier stent (Boston Scientiﬁc) (27).
Study limitations. First, the observed 1-year TLF rate was
2.9% for the control group (CoCr-ZES), which was lower
than the assumed 6.5% used in the study power calculation.
If we had assumed an expected event rate of 2.9% instead of
6.5%, the statistical power of this study to detect non-
inferiority would have been as low as 50%. Second, despite
the all-comer nature of the study population, the event rates
were very low, which may raise the question of under-
reporting. However, periodic monitoring and data audits
were thoroughly performed during this trial. One possible
reason for the low event rates may be that this study had a
2  2 factorial design. Also, the fact that some high-risk
patients met contraindications to cilostazol and had to be
excluded and that all participating patients were treated
with intensiﬁed antiplatelet therapies for 1 month may have
contributed to the lower incidence of TLF. Routine post-
PCI cardiac enzyme measurement was not mandated in
the study, and it may have also led to the lower incidence of
events. There also may be an ethnic or genetic protective
factor, as trials done in East Asian populations have consis-
tently reported lower event rates (28–30). Finally, because
we used visual assessment for presence of LSD, the likeli-
hood of detecting a deformity would be naturally higher in a
more visible stent such as PtCr-EES.
Conclusions
PtCr-EES was noninferior to CoCr-ZES for up to 1 year in
all-comers receiving PCI. Although LSD was observed only
in PtCr-EES, its incidence was rare and was not associated
with future adverse cardiac events.
Figure 5 A Representative Case of Longitudinal Stent Deformation
An 81-year-old woman presented with stable angina pectoris. (A) Baseline angiography showed bifurcation lesion involving an angulated proximal to mid-left anterior descending
artery (LAD) and a big diagonal branch. (B) A 3.0  20-mm Promus Element stent (Boston Scientiﬁc, Natick, Massachusetts) was deployed in the left anterior descending artery
(LAD) (simple crossover technique). (C) After introducing the guidewire to the diagonal branch, no obvious stent deformation was observed. (D) Longitudinal stent deformation
(arrowhead) occurred during advancing adjunctive balloon catheters for kissing ballooning of LAD and diagonal branch. (E) An additional 3.5  15-mm Promus Element stent
was deployed in the proximal LAD overlapping the previous deformed stent. (F) Final angiographic result. The patient experienced no clinical events during the 1-year follow-up
duration after the procedure.
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APPENDIX
For supplemental methods, supplemental tables and a ﬁgure, and a list of
HOST–ASSURE Trial Investigators, please see the online version of this
article.
